Last checked at 1 Mar 2024 13:00
1 March 2024
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Investor Presentation via Investor Meet Company
Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company to the pharmaceutical and biotechnology industry, is pleased to announce that Martin Gouldstone, CEO, and Martin Hudson, CFO, will provide a live presentation relating to the FY2023 results, which were announced on 29 February, via Investor Meet Company on 07 Mar 2024, 10:30 GMT.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 06 Mar 2024, 09:00 GMT, or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Oncimmune via:
https://www.investormeetcompany.com/oncimmune-holdings-plc/register-investor
Investors who already follow Oncimmune on the Investor Meet Company platform will automatically be invited.
For further information:
Oncimmune Holdings plc
contact@oncimmune.com
Singer Capital Markets (Nominated Adviser and Broker)
Philip Davies, Harry Gooden, James Fischer
+44 (0)20 7496 3000
Zeus (Joint Broker)
Dominic King, Victoria Ayton, Dan Bate
+44 (0)20 3829 5000
+44 (0)20 3727 1000
About Oncimmune
Oncimmune is a precision medicine company, specialising in analysing immune interactions through the autoantibody profile. Taking a platform approach to generating insights, Oncimmune is partnering with global pharmaceutical and biotech companies, as well as contract research organisations (CROs) to discover novel biomarkers for the development of more targeted and effective therapies across many immune-mediated diseases. Our mission at Oncimmune is to enable precision medicine. We help our partners to discover novel biomarkers, drug targets and predict treatment efficacy through the application of our platform. We are able to do this by deploying our world class scientific team and our cutting-edge technology platform, built on years of experience in the field. Our aim is to make this an essential tool in drug discovery and development.
Oncimmune is headquartered in the UK, with its discovery and development facility based in Dortmund, Germany and a business development team based in the US and Europe.
For more information, visit www.oncimmune.com